Should I Buy EKSO? EKSO 2026 Analysis

Should You Buy Ekso Bionics Holdings Inc (EKSO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.260

1 Day change

-2.82%

52 Week Range

12.700

Analysis Updated At

2026/01/28

Not a good buy right now for a Beginner, long-term investor with $50k–$100k who wants to act immediately. The stock is trading around $8.50 while the only cited Wall Street target is $6 (even after being raised), recent dilution financing was struck at $8.22 with additional warrants, technicals are not in a clean uptrend, and the latest quarter still shows widening losses despite improving gross margin.

Technical Analysis

Price/Trend: Mixed-to-soft setup. MACD histogram is negative (-0.136) but contracting, implying bearish momentum is easing rather than a confirmed reversal. RSI(6) ~55 is neutral (no strong oversold bounce signal). Moving averages are converging, typically reflecting consolidation/indecision rather than a strong trend. Key levels: Pivot ~8.229 is the near-term line in the sand; holding above it is modestly constructive. Resistance sits at R1 ~9.20 (first meaningful upside hurdle) and R2 ~9.80. Support is S1 ~7.26 then S2 ~6.66. Near-term model read-through: Similar-pattern projection shows slightly negative drift (-0.86% next day, -1.29% next week, -1.85% next month), which does not support an impatient entry.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options market activity is effectively absent (0 open interest/0 volume reported), so sentiment from positioning is not reliable. Volatility metrics are extreme (30D IV ~496% vs historical vol ~104%), suggesting the market prices the stock as highly jumpy, but without traded volume this is more a data/market-structure signal than a clear bullish/bearish crowd view.

Technical Summary

Sell

Buy

Positive Catalysts

News/event-driven: Completed a $5.9M private placement (working capital boost). The preferred shares are convertible at $8.22 (close to current price), and the attached warrants can draw interest if the stock breaks higher.
Strategic backdrop: Prior analyst note referenced a strategic review, which can be a catalyst if it leads to a transaction or operational changes.
Operational: 2025/Q3 gross margin improved to 60.3% (+12.71% YoY), indicating better unit economics.

Neutral/Negative Catalysts

Dilution/overhang: The private placement (convertible preferred at $8.22 plus warrants) can cap upside and increase share count if converted/exercised.
Profitability: 2025/Q3 net loss worsened to -$1.421M (-31.42% YoY) and EPS fell to -0.54 (-64.71% YoY), showing earnings momentum is moving the wrong way.
Wall Street target mismatch: The latest cited price target is $6, which is below the current ~$8.50—an unfavorable setup for new long-term buys.
No supportive flow signals: Hedge fund and insider trends are neutral; no notable accumulation signals. Options tape provides no confirming bullish participation.

Financial Performance

Latest quarter (2025/Q3): Revenue $4.227M (+2.37% YoY) shows only modest growth. Net income declined to -$1.421M (loss widened ~31% YoY) and EPS fell to -0.54 (-64.71% YoY), indicating deteriorating bottom-line performance. The bright spot is gross margin rising to 60.3% (+12.71% YoY), but improved margin has not yet translated into narrowing losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: One highlighted update—H.C. Wainwright maintained a Buy and raised the price target to $6 from $4 (2025-11-18) after a solid Q3 and mention of a strategic review. Pros (Wall St. view): Belief in sales recovery and strategic review upside; maintained Buy rating. Cons (Wall St. view): Even after the increase, the target ($6) is still well below the current price (~$8.50), implying limited upside by that framework and effectively making the stock look ahead-of-analyst valuation today. Influential/political trading: No recent Congress trading data available; hedge funds/insiders show no significant recent trend.

Analyst Rating

Wall Street analysts forecast EKSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKSO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 8.500

Low

Averages

High

Current: 8.500

Low

Averages

High

H.C. Wainwright

Buy

maintain

$4 -> $6

AI Analysis

2025-11-18

Reason

H.C. Wainwright

Price Target

$4 -> $6

AI Analysis

2025-11-18

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Ekso Bionics to $6 from $4 and keeps a Buy rating on the shares. The company reported a solid Q3 report and announced it has initiated a strategic review of the current business, the analyst tells investors in a research note. The firm does not account for any transaction at this time. Ekso's sales recovery in Q3 implies that order delays from the prior quarter "appear to be idiosyncratic," but it remains to be seen if this trend can continue, contends H.C. Wainwright.

Lake Street

Buy

downgrade

$15

2025-07-29

Reason

Lake Street

Price Target

$15

2025-07-29

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Ekso Bionics to $9.50 from $15 and keeps a Buy rating on the shares. Q2 revenue fell "well below" the firm's expectations, attributable to the company's Enterprise Health business. While the firm does not believe investors "should become overly concerned with the company's Q2 results," it recognizes improvements "may not be readily evident prior to the company requiring additional funds."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EKSO

Unlock Now

EKSO Should I Buy

EKSO Should I Buy

Should You Buy Ekso Bionics Holdings Inc (EKSO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch